Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07439250 · ClinicalTrials.gov registry record · Phase 1

A Study of Olomorasib (LY3537982) in Healthy Participants

A Phase 1 study of Healthy, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT07439250 is a Phase 1 study of Healthy that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07439250, a Phase 1 study of Healthy, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.

Conditions Studied

Interventions

  • DRUG Fluconazole
  • DRUG Olomorasib

Study Locations (1)

Florida

  • Fortrea Clinical Research Unit - Daytona Beach - Daytona Beach

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2026-03-02
Est. Completion 2026-04
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT07439250

The ClinicalTrials.gov registry entry for NCT07439250 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Fluconazole is the first listed.

NCT07439250 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT07439250 about?

NCT07439250 is a clinical study titled "A Study of Olomorasib (LY3537982) in Healthy Participants". The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overn...

What is the current status of trial NCT07439250?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-03-02. Estimated completion is 2026-04.

What conditions does trial NCT07439250 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT07439250?

The interventions under investigation include: Fluconazole (DRUG), Olomorasib (DRUG).

Who is sponsoring clinical trial NCT07439250?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07439250 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.